Developer docs
API playgroundTry for free, no card

Search company profiles

TestCard

Full company profile

uuid00052rp

Namestring
TestCard
Legal namestring
TestCard
Websiteurl
TestCard.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

TestCard is a UK-based digital health platform company founded in 2017, headquartered in Scarborough, that converts camera-enabled smart devices into clinical-grade diagnostic scanners using proprietary computer vision software. The platform reads, records, and reports lateral flow and urine dip test results through a three-step Scan-Analyse-Integrate workflow. The company operates three product lines: ClearScreen for clinical settings, an At-Home Testing consumer solution, and Research Solutions for organisations such as Yorkshire Cancer Research and Cancer Research UK. The company is not available for sale in the United States and serves UK and European markets.

The underlying technology combines a mobile application (running on camera-enabled devices) with computer vision analysis software that produces objective test readings. Integrations are delivered via unidirectional middleware connections that avoid direct access to Electronic Medical Systems, and no patient data is stored within the app itself. TestCard has embedded its platform technology into the Roche Cobas Pulse device, enabling OEM distribution alongside its direct enterprise deployments with NHS trusts including Guy's and St Thomas' (GSTT).

TestCard operates a multi-channel go-to-market spanning enterprise sales to NHS trusts, pharmacy distribution (Superdrug), direct-to-consumer at-home testing, and OEM licensing to hardware manufacturers. Revenue streams include software licensing/subscription arrangements with NHS and clinical partners, platform technology licensing (e.g., Roche), and direct-to-consumer at-home testing. Pricing is not publicly disclosed. The company has 11-50 employees and has raised approximately $19M in disclosed funding across multiple rounds since 2017, with West Hill Capital as the most active institutional investor.

Short descriptiontext

TestCard is a UK digital health platform that uses proprietary computer vision to turn camera-enabled smartphones into clinical-grade diagnostic scanners for lateral flow and urine dip tests, serving NHS trusts, pharmacies (Superdrug), OEM partners (Roche), research organisations, and consumers via its ClearScreen app.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersScarborough, United Kingdom
HQ citystring
Scarborough
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
diagnostic software, lateral flow testing, point-of-care diagnostics, computer vision analysis, digital health platform
Industry1 code
PRIMARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code1 code
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Diagnostics Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Software Licensing
TypeSubscription Recurring
Description

TestCard provides the ClearScreen app and platform technology to NHS trusts and clinical partners, likely through licensing or subscription arrangements for the software solution.

testcard.com
2Platform Technology Licensing
TypeLicensing Royalties
Description

TestCard licenses its platform technology to hardware manufacturers like Roche for deployment on devices such as the Cobas Pulse, generating licensing revenue.

testcard.com
3At-Home Testing Services
TypeOne Time License
Description

Direct-to-consumer at-home testing solutions providing diagnostic accuracy, ease of use, affordability and treatment options.

testcard.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 record
1ClearScreen
Description

Digital scanning app for lateral flow and urine dip reading, recording, and reporting solution for clinical settings

testcard.com
Core offering1 text field

TestCard develops a digital platform technology that converts camera-enabled smart devices into clinical-grade scanners for the reading, recording, and reporting of diagnostic test results. Its core offering is the ClearScreen mobile application, which uses proprietary computer vision to perform lateral flow and urine dip test analysis, alongside at-home self-testing and research-data solutions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

TestCard is a digital platform technology that turns camera-enabled smart devices into clinical-grade scanners for accurate reading, recording, and reporting of diagnostic test results. The platform operates as a unified system consisting of three core offerings: ClearScreen (clinical-grade lateral flow and urine dip reading solution for NHS trusts and clinical partners), At-Home Testing (self-testing platform for consumers), and Research Solutions (technology for research organizations providing objective test results and data records). The platform's core workflow involves three steps: Scan (user performs test with smart device support), Analyse (computer vision software reads test results), and Integrate (results are shared digitally with healthcare providers, pharmacies, or integrated into electronic patient records).

Product and service3 records
1ClearScreen
CategoryClinical Diagnostics Software
Description

A clinical-grade lateral flow and urine dip reading, recording, and reporting solution delivered via a mobile application running on camera-enabled devices. It is targeted at NHS trusts and clinical partners for point-of-care diagnostic testing, with simple implementation and low deployment cost.

2At-Home Testing
CategoryConsumer Self-Testing Software
Description

A consumer self-testing platform enabling at-home diagnostic testing with accuracy, ease of use, affordability, and treatment options. It also functions as a route to pre-procedure screening for clinical use.

3Research Solutions
CategoryResearch Data Capture Software
Description

Technological solutions for research organizations, supplying instant, objective test results and digital data records to support clinical and cancer research applications.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TestCard services with key NHS trusts to provide ClearScreen, an accurate and fast lateral flow and urine dip reading, recording, and reporting solution. Implementation includes in-person and remote support during deployment and for the life of the solution.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

TestCard integrates its platform technology into Roche hardware, specifically the deployment of diagnostic technology onto the Roche Cobas Pulse device for point-of-care testing.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership at the forefront of cancer research where TestCard provides technological solutions for vital research, supplying instant, objective test results and data records.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical partnership for deployment of ClearScreen diagnostic testing solution in hospital settings.

5Superdrug
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Pharmacy partnership for distribution and delivery of point-of-care diagnostic testing services.

testcard.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Charitable partnership providing technological solutions for cancer research, supporting vital research with instant, objective test results and data records.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthy.io turns smartphone cameras into clinical-grade urinalysis readers via Dip.io, directly mirroring TestCard's ClearScreen approach for at-home and point-of-care urine dip testing. Both companies sell into health systems and pharmacies and target lay users without specialised hardware.

TypeDirect peer
Description

Scanwell Health builds smartphone-based diagnostic tests, including at-home UTI lateral flow tests read through a mobile app. It is a direct competitor in the connected, app-mediated lateral flow and at-home diagnostics space.

3LumiraDx
TypeBroad incumbent
Description

LumiraDx is a point-of-care diagnostics platform combining a connected device with a broad menu of immunoassays and chemistry tests. It competes with TestCard on the point-of-care diagnostic workflow but via proprietary hardware rather than a smartphone-first approach.

4Cue Health
TypeBroad incumbent
Description

Cue Health offers a connected, cartridge-based diagnostic platform for at-home and clinical use. It overlaps with TestCard in bringing consumer-grade diagnostic testing into connected digital workflows, though via dedicated hardware.

TypeRegional player
Description

Abingdon Health is a UK-based lateral flow assay developer and contract manufacturer. It is a UK regional peer sitting in the same lateral flow value chain and serving overlapping NHS and diagnostic customers.

TypeEmerging player
Description

Visby Medical develops single-use, instrument-free PCR diagnostic devices for point-of-care infectious disease testing. It is an emerging player addressing the same point-of-care diagnostic use cases with a different technology modality.

TypeEmerging player
Description

Ellume builds connected digital diagnostic tests, most notably for influenza and COVID-19, pairing a single-use cartridge with a smartphone app. It overlaps with TestCard in connected consumer diagnostics but with a cartridge-based assay.

TypeBroad incumbent
Description

Color Health operates a large-scale digital diagnostics platform focused on genetic and infectious disease testing, integrated with health systems and employers. It is a broader incumbent in connected, software-mediated diagnostics workflows.

9DnaNudge
TypeRegional player
Description

DnaNudge is a UK-based consumer and clinical DNA testing company using its own lab-on-a-chip platform. It is a UK regional peer combining diagnostics hardware with consumer-facing digital interfaces, similar to TestCard's smartphone-driven model.

10Babylon Health
TypeOthers
Description

Babylon Health is a UK-based digital health platform offering AI-driven triage and remote consultations. While not a diagnostic reader, it is an adjacent ecosystem participant integrating with NHS pathways similar to those TestCard targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TestCard

Digital Diagnostics SoftwareTestCard.com

TestCard is a UK digital health platform that uses proprietary computer vision to turn camera-enabled smartphones into clinical-grade diagnostic scanners for lateral flow and urine dip tests, serving NHS trusts, pharmacies (Superdrug), OEM partners (Roche), research organisations, and consumers via its ClearScreen app.

What TestCard does

TestCard is a UK-based digital health platform company founded in 2017, headquartered in Scarborough, that converts camera-enabled smart devices into clinical-grade diagnostic scanners using proprietary computer vision software. The platform reads, records, and reports lateral flow and urine dip test results through a three-step Scan-Analyse-Integrate workflow. The company operates three product lines: ClearScreen for clinical settings, an At-Home Testing consumer solution, and Research Solutions for organisations such as Yorkshire Cancer Research and Cancer Research UK. The company is not available for sale in the United States and serves UK and European markets.

The underlying technology combines a mobile application (running on camera-enabled devices) with computer vision analysis software that produces objective test readings. Integrations are delivered via unidirectional middleware connections that avoid direct access to Electronic Medical Systems, and no patient data is stored within the app itself. TestCard has embedded its platform technology into the Roche Cobas Pulse device, enabling OEM distribution alongside its direct enterprise deployments with NHS trusts including Guy's and St Thomas' (GSTT).

TestCard operates a multi-channel go-to-market spanning enterprise sales to NHS trusts, pharmacy distribution (Superdrug), direct-to-consumer at-home testing, and OEM licensing to hardware manufacturers. Revenue streams include software licensing/subscription arrangements with NHS and clinical partners, platform technology licensing (e.g., Roche), and direct-to-consumer at-home testing. Pricing is not publicly disclosed. The company has 11-50 employees and has raised approximately $19M in disclosed funding across multiple rounds since 2017, with West Hill Capital as the most active institutional investor.

TestCard firmographics

Firmographics
Name
TestCard
Legal name
TestCard
Website
https://TestCard.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
TestCard is a UK digital health platform that uses proprietary computer vision to turn camera-enabled smartphones into clinical-grade diagnostic scanners for lateral flow and urine dip tests, serving NHS trusts, pharmacies (Superdrug), OEM partners (Roche), research organisations, and consumers via its ClearScreen app.
Ownership category
akta.pro rank

TestCard industry classification

Industry
Product category
Digital Diagnostics Software
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Diagnostic software
  • Lateral flow testing
  • Point-of-care diagnostics
  • Computer vision analysis
  • Digital health platform

Where TestCard is headquartered

Location

Headquarters

HQ city
Scarborough
HQ country
United Kingdom
HQ region
Europe

Markets served

TestCard business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Clinical Software Licensing: TestCard provides the ClearScreen app and platform technology to NHS trusts and clinical partners, likely through licensing or subscription arrangements for the software solution.
  2. Platform Technology Licensing: TestCard licenses its platform technology to hardware manufacturers like Roche for deployment on devices such as the Cobas Pulse, generating licensing revenue.
  3. At-Home Testing Services: Direct-to-consumer at-home testing solutions providing diagnostic accuracy, ease of use, affordability and treatment options.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels2 records

TestCard product offering

Product offering

Core offering

TestCard develops a digital platform technology that converts camera-enabled smart devices into clinical-grade scanners for the reading, recording, and reporting of diagnostic test results. Its core offering is the ClearScreen mobile application, which uses proprietary computer vision to perform lateral flow and urine dip test analysis, alongside at-home self-testing and research-data solutions.

Product overview

TestCard is a digital platform technology that turns camera-enabled smart devices into clinical-grade scanners for accurate reading, recording, and reporting of diagnostic test results. The platform operates as a unified system consisting of three core offerings: ClearScreen (clinical-grade lateral flow and urine dip reading solution for NHS trusts and clinical partners), At-Home Testing (self-testing platform for consumers), and Research Solutions (technology for research organizations providing objective test results and data records). The platform's core workflow involves three steps: Scan (user performs test with smart device support), Analyse (computer vision software reads test results), and Integrate (results are shared digitally with healthcare providers, pharmacies, or integrated into electronic patient records).

Differentiator

Problem solved

Functional benefit

Brands

  • ClearScreen: Digital scanning app for lateral flow and urine dip reading, recording, and reporting solution for clinical settings

Products and services

  • ClearScreen A clinical-grade lateral flow and urine dip reading, recording, and reporting solution delivered via a mobile application running on camera-enabled devices. It is targeted at NHS trusts and clinical partners for point-of-care diagnostic testing, with simple implementation and low deployment cost.
  • At-Home Testing A consumer self-testing platform enabling at-home diagnostic testing with accuracy, ease of use, affordability, and treatment options. It also functions as a route to pre-procedure screening for clinical use.
  • Research Solutions Technological solutions for research organizations, supplying instant, objective test results and digital data records to support clinical and cancer research applications.

Companies that use TestCard

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles5 records

TestCard technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

TestCard partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • NHS TrustscoreStrategic or Co-development PartnerTestCard services with key NHS trusts to provide ClearScreen, an accurate and fast lateral flow and urine dip reading, recording, and reporting solution. Implementation includes in-person and remote support during deployment and for the life of the solution.
  • RochecoreOEM/ Whitelabel/ Licensing PartnerTestCard integrates its platform technology into Roche hardware, specifically the deployment of diagnostic technology onto the Roche Cobas Pulse device for point-of-care testing.
  • Yorkshire Cancer ResearchminorStrategic or Co-development PartnerResearch partnership at the forefront of cancer research where TestCard provides technological solutions for vital research, supplying instant, objective test results and data records.
  • GSTT (Guy's and St Thomas' NHS Foundation Trust)coreStrategic or Co-development PartnerClinical partnership for deployment of ClearScreen diagnostic testing solution in hospital settings.
  • SuperdrugminorChannel Partner/ Reseller/ DistributorPharmacy partnership for distribution and delivery of point-of-care diagnostic testing services.
  • Cancer Research UKminorStrategic or Co-development PartnerCharitable partnership providing technological solutions for cancer research, supporting vital research with instant, objective test results and data records.

Scale indicators1 record

Recent moves3 records

Expansion highlights5 records

TestCard competitors and assessment

Company assessment

Direct peers

  • Healthy.io: Healthy.io turns smartphone cameras into clinical-grade urinalysis readers via Dip.io, directly mirroring TestCard's ClearScreen approach for at-home and point-of-care urine dip testing. Both companies sell into health systems and pharmacies and target lay users without specialised hardware.
  • Scanwell Health: Scanwell Health builds smartphone-based diagnostic tests, including at-home UTI lateral flow tests read through a mobile app. It is a direct competitor in the connected, app-mediated lateral flow and at-home diagnostics space.

Broad incumbents

  • LumiraDx: LumiraDx is a point-of-care diagnostics platform combining a connected device with a broad menu of immunoassays and chemistry tests. It competes with TestCard on the point-of-care diagnostic workflow but via proprietary hardware rather than a smartphone-first approach.
  • Cue Health: Cue Health offers a connected, cartridge-based diagnostic platform for at-home and clinical use. It overlaps with TestCard in bringing consumer-grade diagnostic testing into connected digital workflows, though via dedicated hardware.
  • Color Health: Color Health operates a large-scale digital diagnostics platform focused on genetic and infectious disease testing, integrated with health systems and employers. It is a broader incumbent in connected, software-mediated diagnostics workflows.

Regional players

  • Abingdon Health: Abingdon Health is a UK-based lateral flow assay developer and contract manufacturer. It is a UK regional peer sitting in the same lateral flow value chain and serving overlapping NHS and diagnostic customers.
  • DnaNudge: DnaNudge is a UK-based consumer and clinical DNA testing company using its own lab-on-a-chip platform. It is a UK regional peer combining diagnostics hardware with consumer-facing digital interfaces, similar to TestCard's smartphone-driven model.

Emerging players

  • Visby Medical: Visby Medical develops single-use, instrument-free PCR diagnostic devices for point-of-care infectious disease testing. It is an emerging player addressing the same point-of-care diagnostic use cases with a different technology modality.
  • Ellume: Ellume builds connected digital diagnostic tests, most notably for influenza and COVID-19, pairing a single-use cartridge with a smartphone app. It overlaps with TestCard in connected consumer diagnostics but with a cartridge-based assay.

Others

  • Babylon Health: Babylon Health is a UK-based digital health platform offering AI-driven triage and remote consultations. While not a diagnostic reader, it is an adjacent ecosystem participant integrating with NHS pathways similar to those TestCard targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

TestCard social profiles

Digital presence

TestCard financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TestCard leadership team

Management profile

Number of profiles

Profiles7 records

TestCard funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TestCard M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TestCard

What does TestCard do?

TestCard develops a digital platform technology that converts camera-enabled smart devices into clinical-grade scanners for the reading, recording, and reporting of diagnostic test results. Its core offering is the ClearScreen mobile application, which uses proprietary computer vision to perform lateral flow and urine dip test analysis, alongside at-home self-testing and research-data solutions.

Is TestCard a public or private company?

TestCard is a private company. It is classified as venture growth investor backed and is currently operating.

When was TestCard founded?

TestCard was founded in 2017. It employs 11 to 50 people.

Where is TestCard based?

TestCard is headquartered in Scarborough, United Kingdom, in the Europe region.

How does TestCard make money?

Three revenue lines are on record. Clinical Software Licensing is the primary driver. The others are platform Technology Licensing and at-Home Testing Services.

Who are TestCard's main competitors?

Direct peers on record are Healthy.io and Scanwell Health. Broad incumbents are LumiraDx, Cue Health and Color Health. Regional players are Abingdon Health and DnaNudge. Emerging players are Visby Medical and Ellume. Babylon Health is listed as an others.

Does TestCard have an API?

No public API is recorded for TestCard.

What industry is TestCard in?

TestCard's product category is Digital Diagnostics Software. Its primary akta.pro industry code is HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 3345 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireDigital Diagnostics Market to reach over USD 6.32 Bn by the year 2031 - Exclusive Report by InsightAce AnalyticInsightAce Analytic released a market report forecasting the global digital diagnostics market to reach over USD 6.32 billion by 2031, growing at a CAGR of 18.48%. The report highlights key industry developments, including an exclusive partnership between Roche Tissue Diagnostics and PathAI for AI-enabled pathology algorithms. Other notable activities include TestCard's $10 million funding round and Labcorp's launch of its on-demand testing platform.BusinessCloudMedTech industry veteran named CEO at TestCardTestCard appointed Elmer Monster as CEO, succeeding Chris Craig-Wood, to lead its growth phase. The company raised over $10 million and signed a Roche collaboration for its ClearScreen app. Monster will oversee expansion, including a trial for 6,000 people testing for bladder health.FinSMEsTestCard Raises USD10M in FundingUK-based MedTech company TestCard raised USD10M in funding led by corporate finance firm West Hill Capital. The funds will be used to commercialize existing products, launch new diagnostic tests for conditions like diabetes and flu, and expand its technology platform. TestCard is currently working on FDA approval to enter the US market in early 2023.Just EntrepreneursTestcard raises $10M in latest fundraising round — Just EntrepreneursTestCard Ltd, a British MedTech company, has raised over $10 million in its latest fundraising round, indicating strong market confidence in its business prospects. The funds will be primarily used to commercialize existing products as well as to launch new testing solutions and to support its expansion into the US market. TestCard aims to increase healthcare accessibility through its innovative technology that turns smartphones into clinical-grade scanners for rapid diagnostic testing.The TelegraphThe silent epidemic of midlife UTIs – and what to do about themMidlife urinary tract infections are increasingly common in menopausal women, with Tanya Roberts' death from sepsis linked to a UTI. The article notes 8% of menopausal women experience recurrent UTIs, affecting over 1 million, and suggests vaginal oestrogen and friendly bacteria as remedies.The SunSuperdrug sells first home UTI test and treat kit as demand soars in Covid lockdownSuperdrug launched the UK's first home UTI test and treat kit, responding to a 38% rise in UTI demand over six weeks. The £9.99 TestCard kit uses a mobile app to scan results and redirects to the Online Doctor for medication delivery.Express.co.ukTestCard starts at-home health revolution with UTI checkTestCard will launch an at-home UTI test kit next week, costing £10 for two strips, with results via a smartphone app. The company plans to raise up to £15 million in venture capital next year and aims to be profitable by 2022 with £10 million turnover.UktechnewsTestCard secures £4.5 million Seed Follow On investment from West Hill Capital – UK Tech Investment News by Deal LiteTestCard, a UK medtech firm, secured £4.5m in seed follow-on funding from West Hill Capital. The company will use the funds for product development, regulatory work, and international expansion, with a Series A round anticipated in Q2 2021. Its at-home UTI testing kit launches in November.TechCrunchGet your Startup Alley Exhibitor package plus bonus hotel stayTechCrunch is offering an exhibitor package for Startup Alley at its Disrupt SF conference, which includes exposure to media and investors, a wild card entry to the Startup Battlefield competition, and a complimentary hotel stay. The article highlights past success stories from startups like TestCard and Park & Diamond, noting that exhibiting can lead to significant funding rounds and strategic growth.TechCrunchTestCard founder: Attending Disrupt Berlin is a ‘no-brainer’Luke Heron, CEO of TestCard Diagnostics, a UK-based at-home urine test company founded in 2017, described his positive experience attending TechCrunch Disrupt events as a promotional endorsement for Disrupt Berlin 2019 (December 11–12). TestCard, which embeds urine test kits into postcards and uses smartphone cameras as clinical-grade scanners, previously exhibited at Disrupt SF '17 and Disrupt Berlin '18, where it was named a TC Top Pick. Heron credited the TechCrunch Disrupt platform with helping TestCard secure $1.7 million in funding through media coverage in Engadget and seven VC meetings arranged via CrunchMatch.